Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus TPF induction followed by concurrent chemoradiotherapy and adjuvant therapy in locally advanced nasopharyngeal carcinoma
ChiCTR2300072053Phase 2Not yet recruiting
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, docetaxel, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Primary endpoint: complete response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
tislelizumabdocetaxelcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300072053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072053.